Oncology Pipeline & Trials
Oncology Pipeline Snapshot as of January 29, 2019
- Discovery Projects
-
18Phase 1
-
8Phase 2
-
14Phase 3
-
6Registration
- Total46
|
Compound Name |
Indication |
Phase |
Submission Type |
Compound Type |
|---|---|---|---|---|
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Merkel Cell Carcinoma (E.U.) (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ PF-04518600 (OX40) for: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ PF-05082566 (4-1BB) for: Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer (Biologic) | Phase 1 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ talazoparib (MDV3800) and Array's MEK inhibitor for: Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ talazoparib (MDV3800) for: Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ talazoparib (MDV3800) for: Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Combo w/ talazoparib (MDV3800) for: 1st Line Ovarian Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Cancer (Biologic) | Phase 1 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Gastric Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Urothelial Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (BREAKTHROUGH) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
Anti PD-L1 Inhibitor |
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
dacomitinib (PF-00299804)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
pan-HER Inhibitor |
1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (E.U.) | Registration | New Molecular Entity | Small Molecule |
|
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD Mechanism of Action:
Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR) |
Cancer | Phase 1 | New Molecular Entity | Small Molecule |
|
glasdegib (PF-04449913)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
SMO (smoothened) antagonist |
Combo w/ low-dose cytarabine (LDAC) for: Acute Myeloid Leukemia (E.U.) | Phase 2 | New Molecular Entity | Small Molecule |
|
glasdegib (PF-04449913)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Medicines Mechanism of Action:
SMO (smoothened) antagonist |
Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Small Molecule |
